What is the role of sipuleucel-T (Provenge) in the treatment of hormone-refractory prostate cancer?

Updated: Dec 29, 2020
  • Author: Martha K Terris, MD, FACS; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Answer

Answer

In April 2010, sipuleucel-T (Provenge) was approved for asymptomatic or minimally symptomatic prostate cancer with metastases resistant to standard hormone treatment. Sipuleucel-T is an autologous cellular immunotherapy prepared from peripheral blood mononuclear cells, including antigen presenting cells (APCs). These cells are activated during a defined culture period with recombinant human protein consisting of prostatic acid phosphatase, an antigen expressed in prostate cancer tissue.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!